<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23437398</article-id><article-id pub-id-type="pmc">3578811</article-id><article-id pub-id-type="publisher-id">PONE-D-12-04768</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0057554</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Cardiovascular</subject><subj-group><subject>Acute Cardiovascular Problems</subject><subject>Coronary Artery Disease</subject><subject>Heart Failure</subject><subject>Myocardial Infarction</subject><subject>Peripheral Vascular Diseases</subject><subject>Vascular Biology</subject></subj-group></subj-group><subj-group><subject>Drugs and Devices</subject><subj-group><subject>Drug Information</subject><subject>Drug Research and Development</subject></subj-group></subj-group><subj-group><subject>Oncology</subject><subj-group><subject>Cancer Treatment</subject><subj-group><subject>Chemotherapy and Drug Treatment</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Weekly Doxorubicin Increases Coronary Arteriolar Wall and Adventitial Thickness</article-title><alt-title alt-title-type="running-head">Coronary Arteriolar Thickness after DOX</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Eckman</surname><given-names>Delrae M.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Stacey</surname><given-names>R. Brandon</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Rowe</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>D&#x02032;Agostino</surname><given-names>Ralph</given-names><suffix>Jr</suffix></name><xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kock</surname><given-names>Nancy D.</given-names></name><xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Sane</surname><given-names>David C.</given-names></name><xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Torti</surname><given-names>Frank M.</given-names></name><xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Yeboah</surname><given-names>Joseph</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Workman</surname><given-names>Susan</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Lane</surname><given-names>Kimberly S.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Hundley</surname><given-names>W. Gregory</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Department of Internal Medicine (Section on Cardiology), Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
</aff><aff id="aff3">
<label>3</label>
<addr-line>Department of Biostatistical Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
</aff><aff id="aff4">
<label>4</label>
<addr-line>Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
</aff><aff id="aff5">
<label>5</label>
<addr-line>Department of Internal Medicine Division of Cardiology, Virginia Tech Carilion School of Medicine, Roanoke, Virginia, United States of America</addr-line>
</aff><aff id="aff6">
<label>6</label>
<addr-line>Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
</aff><aff id="aff7">
<label>7</label>
<addr-line>Departments of Internal Medicine (Section on Cardiology) and Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Salloum</surname><given-names>Fadi N</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>Virginia Commonwealth University Medical Center, Virginia, United States of America</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>ghundley@wakehealth.edu</email></corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Scientific and editorial support: DE FT RR DS JY SW KL. Conceived and designed the experiments: WGH NK. Performed the experiments: NK WGH. Analyzed the data: DME RBS RR RD SW KL WGH. Contributed reagents/materials/analysis tools: NK WGH. Wrote the paper: DME RBS WGH.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2013</year></pub-date><volume>8</volume><issue>2</issue><elocation-id>e57554</elocation-id><history><date date-type="received"><day>9</day><month>2</month><year>2012</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2013</year></date></history><permissions><copyright-statement>&#x000a9; 2013 Eckman et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Eckman et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>Doxorubicin (DOX) is associated with premature cardiovascular events including myocardial infarction. This study was performed to determine if the weekly administration of DOX influenced coronary arteriolar medial and/or adventitial wall thickening.</p></sec><sec><title>Methods</title><p>Thirty-two male Sprague-Dawley rats aged 25.1&#x000b1; 2.4 weeks were randomly divided into three groups and received weekly intraperitoneal injections of normal saline (saline, n&#x0200a;=&#x0200a;7), or low (1.5 mg/kg to 1.75 mg/kg, n&#x0200a;=&#x0200a;14) or high (2.5 mg/kg, n&#x0200a;=&#x0200a;11) doses of DOX. The animals were treated for 2&#x02013;12 weeks, and euthanized at pre-specified intervals (2, 4, 7, or 10+ weeks) to obtain histopathologic assessments of coronary arteriolar lumen diameter, medial wall thickness, adventitial wall thickness, and total wall thickness (medial thickness + adventitial thickness).</p></sec><sec><title>Results</title><p>Lumen diameter was similar across all groups (saline: 315&#x000b1;34 &#x000b5;m, low DOX: 286&#x000b1;24 &#x000b5;m, high DOX: 242&#x000b1;27 &#x000b5;m; <italic>p</italic>&#x0200a;=&#x0200a;0.22). In comparison to animals receiving weekly saline, animals receiving weekly injections of 2.5 mg/kg of DOX experienced an increase in medial (23&#x000b1;2&#x000b5;m vs. 13&#x000b1;3&#x000b5;m; <italic>p</italic>&#x0200a;=&#x0200a;0.005), and total wall thickness (51&#x000b1;4&#x000b5;m vs. 36&#x000b1;5&#x000b5;m; <italic>p</italic>&#x0200a;=&#x0200a;0.022), respectively. These increases, as well as adventitial thickening became more prominent after normalizing for lumen diameter (<italic>p</italic>&#x0003c;0.05 to <italic>p</italic>&#x0003c;0.001) and after adjusting for age, weight, and total cumulative DOX dose (<italic>p</italic>&#x0200a;=&#x0200a;0.02 to <italic>p</italic>&#x0200a;=&#x0200a;0.01). Animals receiving low dose DOX trended toward increases in adventitial and total wall thickness after normalization to lumen diameter and accounting for age, weight, and total cumulative DOX dose (<italic>p</italic>&#x0200a;=&#x0200a;0.06 and 0.09, respectively).</p></sec><sec><title>Conclusion</title><p>In conclusion, these data demonstrate that weekly treatment of rats with higher doses of DOX increases coronary arteriolar medial, adventitial, and total wall thickness. Future studies are warranted to determine if DOX related coronary arteriolar effects are reversible or preventable, exacerbate the known cardiomyopathic effects of DOX, influence altered resting or stress-induced myocardial perfusion, or contribute to the occurrence of myocardial infarction.</p></sec></abstract><funding-group><funding-statement>Research supported in part by National Institute of Health (<ext-link ext-link-type="uri" xlink:href="http://www.nih.gov">http://www.nih.gov</ext-link>) grants R21CA109224, R33CA12196, and a grant (BCTR0707769) from the Susan G. Komen Foundation (<ext-link ext-link-type="uri" xlink:href="http://ww5.komen.org">http://ww5.komen.org</ext-link>). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="6"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Cardiovascular (CV) events including myocardial infarction (MI), stroke, and congestive heart failure (CHF) are the second leading cause of premature morbidity and mortality for those surviving beyond 5 years of their initial diagnosis for breast cancer or a hematologic malignancy such as Hodgkin's disease or Non-Hodgkin's lymphoma <xref rid="pone.0057554-Aleman1" ref-type="bibr">[1]</xref>&#x02013;<xref rid="pone.0057554-Jensen1" ref-type="bibr">[3]</xref>. A commonality among treatment for these cancers is the administration of anthracycline chemotherapy with agents such as doxorubicin (DOX). Several studies have identified mechanisms by which the administration of DOX is associated with myocellular injury and consequent CHF <xref rid="pone.0057554-Aries1" ref-type="bibr">[4]</xref>&#x02013;<xref rid="pone.0057554-Timolati1" ref-type="bibr">[8]</xref>. Importantly, however, there are relatively few studies that have focused on understanding potential mechanisms by which patients exposed to DOX or other anthracyclines might experience altered myocardial blood flow or sustain a MI.</p><p>To this end, we investigated the association between the administration of DOX and histopathologic changes in coronary arteriolar microcirculatory arterial segments. To address this issue, we performed a series of studies to determine the relationship between DOX administration and measures of coronary arteriolar wall thickening. In this study, we evaluated 2 doses of DOX in a rat model without coronary arterial atherosclerosis. These doses were selected to mimic doses commonly administered to patients receiving DOX for treatment of breast cancer or lymphoma. We measured the thickening of the media as well as the adventitia of the coronary microcirculatory arteriolar segments.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study Design</title><p>This study was performed at the Wake Forest University School of Medicine as part of a protocol approved by the Institutional Animal Care and Use Committee (Assurance #A04-137) of Wake Forest University, and was funded by the National Institutes of Health (study identifier R21CA109224). A total of thirty-two male Sprague-Dawley rats (a subset of animals previously reported <xref rid="pone.0057554-Lightfoot1" ref-type="bibr">[9]</xref>), aged 25.1&#x000b1;2.4 weeks, were randomly assigned into one of three groups: Group 1 (n&#x0200a;=&#x0200a;7) served as our control group and received weekly intraperitoneal injections of normal saline (saline); Group 2 (n&#x0200a;=&#x0200a;14) received weekly intraperitoneal injections of a low dose of DOX (low DOX, 1.5 mg/kg/week, n&#x0200a;=&#x0200a;12 or 1.75 mg/kg/wk, n&#x0200a;=&#x0200a;2); Group 3 (n&#x0200a;=&#x0200a;11) received weekly intraperitoneal injections of a high dose of DOX (2.5 mg/kg/week).</p><p>At the 2, 4, 7, and 10&#x02013;12 week intervals, rats from the DOX treatment groups were randomly selected for necropsy and histopathologic examination of the coronary arteriolar and adventitial diameters. Histopathological examination of saline treated animals was conducted at 2 weeks in 1 animal and at the end of the 10 week study in the other 6 animals. During receipt of saline and DOX, rat physical appearance and weights were routinely monitored. If the physical appearance of rats reached a level of 5 or body weight decreased greater than 25% from the start of study (see <xref ref-type="table" rid="pone-0057554-t001">Table 1</xref>), animals were considered to be in poor condition (near death), withdrawn from the study and euthanized.</p><table-wrap id="pone-0057554-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057554.t001</object-id><label>Table 1</label><caption><title>Effect of DOX on rat physical parameters and EF measurements (mean &#x000b1; standard error of the mean.</title></caption><alternatives><graphic id="pone-0057554-t001-1" xlink:href="pone.0057554.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Weeks in study</td><td align="left" rowspan="1" colspan="1">Rat weight, gm</td><td align="left" rowspan="1" colspan="1">Physical Appearance score</td><td align="left" rowspan="1" colspan="1">EF Measurements</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Saline</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">483&#x000b1;37 (n&#x0200a;=&#x0200a;7)</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;7)</td><td align="left" rowspan="1" colspan="1">77&#x000b1;3 (n&#x0200a;=&#x0200a;7)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">488&#x000b1;35 (n&#x0200a;=&#x0200a;7)</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;0.3 (n&#x0200a;=&#x0200a;7)</td><td align="left" rowspan="1" colspan="1">73&#x000b1;2 (n&#x0200a;=&#x0200a;5)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">521&#x000b1;30 (n&#x0200a;=&#x0200a;6)</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;6)</td><td align="left" rowspan="1" colspan="1">77&#x000b1;3 (n&#x0200a;=&#x0200a;6)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">538&#x000b1;29 (n&#x0200a;=&#x0200a;6)<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;6)</td><td align="left" rowspan="1" colspan="1">78&#x000b1;2 (n&#x0200a;=&#x0200a;5)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10+</td><td align="left" rowspan="1" colspan="1">544&#x000b1;29 (n&#x0200a;=&#x0200a;6)<xref ref-type="table-fn" rid="nt103">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;6)</td><td align="left" rowspan="1" colspan="1">77&#x000b1;1 (n&#x0200a;=&#x0200a;4)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Low Doxorubicin (1.5&#x02013;1.75 mg/kg/wk)</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">415&#x000b1;12 (n&#x0200a;=&#x0200a;14)</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;14)</td><td align="left" rowspan="1" colspan="1">77&#x000b1;1 (n&#x0200a;=&#x0200a;14)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">411&#x000b1;12 (n&#x0200a;=&#x0200a;14)</td><td align="left" rowspan="1" colspan="1">1.9&#x000b1;0.1 (n&#x0200a;=&#x0200a;14)</td><td align="left" rowspan="1" colspan="1">75&#x000b1;1 (n&#x0200a;=&#x0200a;12)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">401&#x000b1;14 (n&#x0200a;=&#x0200a;9)</td><td align="left" rowspan="1" colspan="1">2.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;9)</td><td align="left" rowspan="1" colspan="1">73&#x000b1;3 (n&#x0200a;=&#x0200a;6)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">389&#x000b1;13 (n&#x0200a;=&#x0200a;8)<xref ref-type="table-fn" rid="nt104">**</xref>
</td><td align="left" rowspan="1" colspan="1">3.8&#x000b1;0.4 (n&#x0200a;=&#x0200a;8)#</td><td align="left" rowspan="1" colspan="1">73&#x000b1;3 (n&#x0200a;=&#x0200a;8)<xref ref-type="table-fn" rid="nt106">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10+</td><td align="left" rowspan="1" colspan="1">368&#x000b1;16 (n&#x0200a;=&#x0200a;3)<xref ref-type="table-fn" rid="nt104">**</xref>
</td><td align="left" rowspan="1" colspan="1">3.3&#x000b1;0.3 (n&#x0200a;=&#x0200a;3)#</td><td align="left" rowspan="1" colspan="1">67&#x000b1;9 (n&#x0200a;=&#x0200a;3)<xref ref-type="table-fn" rid="nt106">&#x02020;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>High Doxorubicin (2.5 mg/kg/wk)</bold>
</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">467&#x000b1;17 (n&#x0200a;=&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">1.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">70&#x000b1;2 (n&#x0200a;=&#x0200a;11)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">460&#x000b1;15 (n&#x0200a;=&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">1.8&#x000b1;0.1 (n&#x0200a;=&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">69&#x000b1;2 (n&#x0200a;=&#x0200a;9)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">418&#x000b1;11 (n&#x0200a;=&#x0200a;11)</td><td align="left" rowspan="1" colspan="1">3.4&#x000b1;0.2 (n&#x0200a;=&#x0200a;11)#</td><td align="left" rowspan="1" colspan="1">65&#x000b1;3 (n&#x0200a;=&#x0200a;11)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">408&#x000b1;10 (n&#x0200a;=&#x0200a;5)<xref ref-type="table-fn" rid="nt104">**</xref>
</td><td align="left" rowspan="1" colspan="1">4.4&#x000b1;0.4 (n&#x0200a;=&#x0200a;5)#</td><td align="left" rowspan="1" colspan="1">55&#x000b1;6 (n&#x0200a;=&#x0200a;4)<xref ref-type="table-fn" rid="nt107">&#x02021;</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">10+</td><td align="left" rowspan="1" colspan="1">438&#x000b1;0 (n&#x0200a;=&#x0200a;1)</td><td align="left" rowspan="1" colspan="1">3.0&#x000b1;0.0 (n&#x0200a;=&#x0200a;1)#</td><td align="left" rowspan="1" colspan="1">74&#x000b1;0 (n&#x0200a;=&#x0200a;1)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt101"><label/><p>Number of animals in treatment group at any given time is indicated within the parentheses.</p></fn><fn id="nt102"><label/><p>Average appearance score of animals in study, where 1 &#x0200a;=&#x0200a; excellent, active; 2 &#x0200a;=&#x0200a; good: active, slight hair loss; 3 &#x0200a;=&#x0200a; fair: less active, slight bloating; 4 &#x0200a;=&#x0200a; poor: reluctant to move, poor appetite and diarrhea; 5 &#x0200a;=&#x0200a; critical: marked pallor, lethargic.</p></fn><fn id="nt103"><label>*</label><p>increase in weight relative to baseline <italic>p</italic>&#x0003c;0.0001</p></fn><fn id="nt104"><label>**</label><p>decrease in weight relative to baseline <italic>p</italic>&#x02264;0.001</p></fn><fn id="nt105"><label/><p>#increase in appearance score relative to baseline <italic>p</italic>&#x0003c;0.0001</p></fn><fn id="nt106"><label>&#x02020;</label><p>decrease in LVEF relative to baseline <italic>p</italic>&#x0200a;=&#x0200a;0.005</p></fn><fn id="nt107"><label>&#x02021;</label><p>decrease in LVEF relative to baseline <italic>p</italic>&#x0200a;=&#x0200a;0.01</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Animal Euthanasia and Pathology Data</title><p>After animal euthanasia (ketamine/xylazine 80/12 mg/kg IM followed by CO<sub>2</sub> asphyxiation), gross examination of the rats was performed. The hearts were excised, the aorta was cannulated, and then the heart was mounted on a Langendorff apparatus, pressurized to 52 cm H<sub>2</sub>O, and perfused with paraformaldehyde for 20 minutes. The heart was then transferred to chilled paraformaldehyde for 24 hours followed by a solution of 70% ethanol. Appropriate sections were trimmed to obtain the middle short axis view. As shown in <xref ref-type="fig" rid="pone-0057554-g001">Figure 1</xref> (upper left panel), this section was obtained at &#x000bd; the distance from the mitral annulus to the cardiac apex. The sections were embedded in paraffin, processed routinely for histology, cut at 4 to 6 &#x000b5;m, and stained with Mason's trichrome to clearly visualize the smooth muscle and adventitial boundaries (<xref ref-type="fig" rid="pone-0057554-g001">Figure 1</xref>, upper right and lower right). Images were digitally scanned utilizing a Hammatsu Nanozoomer 2.0 HT virtual imaging system equipped with an Olympus objective x40 NA 0.75 (Digital Imaging Core, Wake Forest University School of Medicine) and resolved at 40X to 60X utilizing Nanozoomer Digital Pathology Virtual Slide Viewer (NPD.view, version 1.2.36, Hammatsu Photonics KK, Japan) to assess lumen, medial and adventitial circumferences of the 3 largest, similar caliber intramyocardial arteries. Values for individual artery lumen, medial and adventitial circumferences (LC, MC, and AC; respectively) were obtained by tracing the region of interest (NDP.view) as indicated by the green arrowheads in <xref ref-type="fig" rid="pone-0057554-g001">Figure 1</xref> (lower left panel). Values for LC, MC, and AC were used to obtain specific diameters, radius and wall thickness values as indicated below:</p><fig id="pone-0057554-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057554.g001</object-id><label>Figure 1</label><caption><title>Acquisition of histological samples.</title><p>Schematic representation that illustrates the location, selection, and analysis method of the histological specimens used to measure arteriolar wall thickness. Sectioned histologic specimens were obtained in a short axis plane located &#x000bd; the distance between the mitral annulus and the apex of the left ventricle (top left). In the top right panel, a low resolution image of the rat myocardium at 2x with high resolution is shown with an insert of a coronary arteriolar vessel at 20x (bottom right). Values for individual artery lumen, medial and adventitial circumferences (LC, MC, and AC, respectively) were obtained by tracing the region of interest using the digital imaging analysis program NDP.view (indicated in green, bottom right). The bottom left panel shows how the circumference data were used to find the lumen, medial, and adventitial radii (LR, MR, and AR, respectively) in order to calculate average diameters and wall thickness.</p></caption><graphic xlink:href="pone.0057554.g001"/></fig><p>Lumen calculations:</p><list list-type="bullet"><list-item><p>Average Lumen Diameter (LD) &#x0200a;=&#x0200a; LC/&#x003c0;</p></list-item><list-item><p>Average Lumen Radius (LR) &#x0200a;=&#x0200a; LD/2</p></list-item></list><p>Medial calculations:</p><list list-type="bullet"><list-item><p>Average Medial Diameter (MD) &#x0200a;=&#x0200a; MC/&#x003c0;</p></list-item><list-item><p>Average Medial Radius (MR) &#x0200a;=&#x0200a; MD/2</p></list-item><list-item><p>Average Medial Thickness (MT) &#x0200a;=&#x0200a; MR - LR</p></list-item></list><p>Adventitial calculations:</p><list list-type="bullet"><list-item><p>Average Adventitial Diameter (AD) &#x0200a;=&#x0200a; AC/&#x003c0;</p></list-item><list-item><p>Average Adventitial Radius (AR) &#x0200a;=&#x0200a; AD/2</p></list-item><list-item><p>Average Adventitial Wall Thickness (AT) &#x0200a;=&#x0200a; AR &#x02013; MR</p></list-item></list><p>Full Thickness (FT):</p><list list-type="bullet"><list-item><p>FT &#x0200a;=&#x0200a; MT+AT</p></list-item></list><p>Lumen diameter (LD), medial wall thickness, adventitial thickness, and full thickness (medial thickness + adventitial thickness) were calculated and presented in the absence (<xref ref-type="table" rid="pone-0057554-t002">Table 2</xref>) and presence (<xref ref-type="table" rid="pone-0057554-t003">Table 3</xref>) of normalization to LD.</p><table-wrap id="pone-0057554-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057554.t002</object-id><label>Table 2</label><caption><title>Effect of Doxorubicin (DOX) on coronary artery lumen diameter, medial thickness, adventitial thickness and total wall thickness.</title></caption><alternatives><graphic id="pone-0057554-t002-2" xlink:href="pone.0057554.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Number of animals in analysis</td><td align="left" rowspan="1" colspan="1">Lumen Diameter (&#x000b5;m)</td><td align="left" rowspan="1" colspan="1">Medial Thickness (&#x000b5;m)</td><td align="left" rowspan="1" colspan="1">Adventitial Thickness (&#x000b5;m)</td><td align="left" rowspan="1" colspan="1">Total Wall Thickness (&#x000b5;m)</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Saline</bold>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">315&#x000b1;34</td><td align="left" rowspan="1" colspan="1">13&#x000b1;3</td><td align="left" rowspan="1" colspan="1">23&#x000b1;4</td><td align="left" rowspan="1" colspan="1">36&#x000b1;5</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Low Doxorubicin</bold>
</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">286&#x000b1;2</td><td align="left" rowspan="1" colspan="1">12&#x000b1;2</td><td align="left" rowspan="1" colspan="1">24&#x000b1;3</td><td align="left" rowspan="1" colspan="1">36&#x000b1;4</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>High Doxorubicin</bold>
</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">242&#x000b1;27</td><td align="left" rowspan="1" colspan="1">22&#x000b1;2**</td><td align="left" rowspan="1" colspan="1">28&#x000b1;3</td><td align="left" rowspan="1" colspan="1">51&#x000b1;4*</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt108"><label/><p>Low Doxorubicin: 1.5 mg/kg to 1.75 mg/kg</p></fn><fn id="nt109"><label/><p>High Doxorubicin: 2.5 mg/kg</p></fn><fn id="nt110"><label/><p>Values are expressed as the unadjusted mean &#x000b1; SEM. All statistical comparisons shown are between different doxorubicin doses to normal saline (*<italic>p</italic>&#x0200a;=&#x0200a;0.02, **<italic>p</italic>&#x0200a;=&#x0200a;0.005 in comparison to normal saline).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0057554-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057554.t003</object-id><label>Table 3</label><caption><title>Effect of Doxorubicin (DOX) on coronary artery medial thickness, adventitial thickness and total wall thickness: normalized to lumen diameter.</title></caption><alternatives><graphic id="pone-0057554-t003-3" xlink:href="pone.0057554.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Treatment</td><td align="left" rowspan="1" colspan="1">Number of animals in analysis</td><td align="left" rowspan="1" colspan="1">Medial Thickness/LD</td><td align="left" rowspan="1" colspan="1">Adventitial Thickness/LD</td><td align="left" rowspan="1" colspan="1">Total Wall Thickness/LD</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">
<bold>Saline</bold>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0.04&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">0.07&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">0.12&#x000b1;0.03</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>Low Doxorubicin</bold>
</td><td align="left" rowspan="1" colspan="1">14</td><td align="left" rowspan="1" colspan="1">0.04&#x000b1;0.01</td><td align="left" rowspan="1" colspan="1">0.09&#x000b1;0.02</td><td align="left" rowspan="1" colspan="1">0.14&#x000b1;0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">
<bold>High Doxorubicin</bold>
</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">0.10&#x000b1;0.01***</td><td align="left" rowspan="1" colspan="1">0.14&#x000b1;0.02 *</td><td align="left" rowspan="1" colspan="1">0.25&#x000b1;0.02**</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="nt111"><label/><p>Low Doxorubicin: 1.5 mg/kg to 1.75 mg/kg</p></fn><fn id="nt112"><label/><p>High Doxorubicin: 2.5 mg/kg</p></fn><fn id="nt113"><label/><p>Values are expressed as the unadjusted mean &#x000b1; SEM. All statistical comparisons shown are between different doxorubicin doses to normal saline (*<italic>p</italic>&#x0003c;0.05, **<italic>p</italic>&#x0003c;0.01, and ***<italic>p</italic>&#x0003c;0.001).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2c"><title>Statistical Analyses</title><p>Animals within each group were assessed at pre-specified time intervals. All analyses that compared groups at a fixed point in time were performed first using analysis of variance (ANOVA), then using analysis of covariance (ANCOVA) to adjust for age, weight, and the total cumulative dose of DOX. In addition, separate analyses were performed to account for the potential influence of time or duration of treatment on our results. Only when there were overall significant differences in appearance among the 3 groups would pair-wise comparisons of least means squares be tested with Student's t-tests between the saline and the low- and high-DOX groups. Comparisons were made to determine whether the thickness of the adventitia, thickness of the media, and the total thickness of the media-adventitia differed between DOX and saline treatment groups. All values are reported as mean &#x000b1; the standard error of the mean (SEM), and unless stated otherwise, a value of <italic>p</italic>&#x0003c;0.05 was considered significant. For all analyses, SAS version 9.1 was used.</p></sec></sec><sec id="s3"><title>Results</title><p>Characteristics pertaining to the animals are provided in <xref ref-type="table" rid="pone-0057554-t001">Table 1</xref>. As shown, the animals receiving saline remained healthy throughout the study. Those receiving low DOX developed signs of poor health at 2 weeks that became more severe by 7 weeks into the study (<italic>p</italic>&#x0003c;0.0001; <xref ref-type="table" rid="pone-0057554-t001">Table 1</xref>). Those animals receiving 2.5 mg/kg/week also experienced signs of poor health that began 2 weeks into receipt of DOX and worsened by the 4<sup>th</sup> week of study (<italic>p</italic>&#x0003c;0.0001; <xref ref-type="table" rid="pone-0057554-t001">Table 1</xref>). In animals receiving either low or high weekly doses of DOX, LVEF declined relative to baseline (<italic>p</italic>&#x0200a;=&#x0200a;0.01 to 0.005; <xref ref-type="table" rid="pone-0057554-t001">Table 1</xref>).</p><p>Lumen diameter, medial wall thickness, adventitial thickness and total arterial wall thickness are shown in <xref ref-type="table" rid="pone-0057554-t002">Table 2</xref>. Values for LD in those animals receiving saline (n&#x0200a;=&#x0200a;7), low DOX (n&#x0200a;=&#x0200a;14) and high DOX (n&#x0200a;=&#x0200a;11) were similar (<italic>p</italic>&#x0200a;=&#x0200a;0.22, <xref ref-type="table" rid="pone-0057554-t002">Table 2</xref>). As shown, animals exposed to high DOX exhibited an increased medial thickness (<italic>p</italic>&#x0200a;=&#x0200a;0.005), and total thickness (<italic>p</italic>&#x0200a;=&#x0200a;0.02) compared to animals receiving saline (<xref ref-type="fig" rid="pone-0057554-g002">Figure 2</xref> and <xref ref-type="table" rid="pone-0057554-t002">Table 2</xref>).</p><fig id="pone-0057554-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057554.g002</object-id><label>Figure 2</label><caption><title>Coronary arteriolar histology in saline versus Doxorubicin sample.</title><p>Coronary arteriolar histology from an animal treated with normal saline (1cc/week) for 7&#x02013;10 weeks (left) with a coronary arteriole obtained from an animal treated with 2.5 mg/kg/week of doxorubicin for 10 weeks (right). Compared with the normal saline treated artery, the doxorubicin treated artery has increased medial and adventitial thickness.</p></caption><graphic xlink:href="pone.0057554.g002"/></fig><p>When normalized to LD (<xref ref-type="table" rid="pone-0057554-t003">Table 3</xref>), high DOX animals experienced an increase in medial wall thickness, adventitial thickness and total wall thickness (<italic>p</italic>&#x0003c;0.05 to &#x0003c;0.001, <xref ref-type="table" rid="pone-0057554-t003">Table 3</xref>). We assessed the medial, adventitial, and total wall thickness normalized to LD after accounting for potential differences in age, amount of DOX received and treatment duration by the animals. As shown in <xref ref-type="fig" rid="pone-0057554-g003">Figure 3</xref>, there were trends toward an increase in adventitial and total wall thickness in the animals receiving low DOX. In animals receiving high DOX, medial, adventitial, and total wall thickness were elevated relative to saline controls after accounting for age, weight and total dose of DOX received (<xref ref-type="fig" rid="pone-0057554-g003">Figure 3</xref>).</p><fig id="pone-0057554-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0057554.g003</object-id><label>Figure 3</label><caption><title>Adjusted medial, adventitial, and total wall thickness.</title><p>These data summarize the effect of saline (n&#x0200a;=&#x0200a;7), low (1.5 mg/kg to 1.75 mg/kg, n&#x0200a;=&#x0200a;14) or high (2.5 mg/kg, n&#x0200a;=&#x0200a;11) doses of doxorubicin (DOX) on coronary arteriolar medial, adventitial, and total wall thickness after normalization to lumen diameter and adjusting for animal age, weight, and duration of treatment. Data shown are adjusted mean &#x000b1; the standard error of the mean (SEM). P-values are provided for comparisons between saline and doxorubicin treated groups (analysis of covariance).</p></caption><graphic xlink:href="pone.0057554.g003"/></fig><p>To examine the potential influence of treatment duration on wall thickness values, we categorized duration of exposure into 3 intervals (2 or 4, 7 and 10 weeks). Because of the relatively few numbers of animals available for study of the 2 week interval, the animals within the 2 and 4 week groups were combined. For the high DOX animals, those with the shortest duration of exposure (2 or 4 weeks) had the highest levels of adventitial, medial and total wall thickness relative to those treated for 7 or 10 weeks. This observation was strongest for the adventitial measures (<italic>p</italic>&#x0003c; 0.009 for comparisons) followed by the total wall thickness (<italic>p</italic>&#x0003c;0.04 for comparisons). In the low DOX and saline groups, the effect of duration of treatment was not significant for any thickness measure throughout the duration of the study.</p></sec><sec id="s4"><title>Discussion</title><p>The results of this study indicate: a) the administration of 2.5 mg/kg/week of DOX increases the thickness of the walls of coronary arterioles of Sprague-Dawley rats, driven primarily by an increase in medial thickening (<xref ref-type="table" rid="pone-0057554-t002">Table 2</xref>); b) these increases persist after indexing the regions of wall thickness for the LD of the vessel, and after accounting for animal age, weight, and the total cumulative amount of DOX received (<xref ref-type="table" rid="pone-0057554-t003">Table 3</xref> and <xref ref-type="fig" rid="pone-0057554-g003">Figure 3</xref>); c) when duration of treatment is assessed, those animals receiving 2.5 mg/kg/week for &#x02264;4 weeks experience greater amounts of arterial thickening than those surviving for &#x02265;10 weeks of treatment; and d) after adjustment for age and DOX dose, lower doses of DOX (1.5 mg/kg/week) trend toward an increase in the total wall thickness of coronary arterial segments (<xref ref-type="fig" rid="pone-0057554-g003">Figure 3</xref>). This trend is primarily related to trends in an increase in the thickening of the adventitia (<xref ref-type="fig" rid="pone-0057554-g003">Figure 3</xref>).</p><p>Anthracycline-based chemotherapeutic regimens (including those that incorporate DOX) are among the most widely used regimens to treat malignancies. Today, more than 60,000 patients receive anthracyclines each year to treat leukemia and lymphoma, and breast, uterine, ovarian and lung cancer <xref rid="pone.0057554-Floyd1" ref-type="bibr">[10]</xref>&#x02013;<xref rid="pone.0057554-Singal1" ref-type="bibr">[12]</xref>. One-half of all patients exposed to anthracyclines, including DOX, demonstrate some degree of cardiac dysfunction 10 to 20 years after chemotherapy, and 5% of them develop overt CHF <xref rid="pone.0057554-Silber1" ref-type="bibr">[11]</xref>. To date, much of the research into the primary mechanism of anthracycline cardiomyopathy has focused on the direct effect of anthracyclines on the left ventricular myocytes <xref rid="pone.0057554-Kotamraju1" ref-type="bibr">[5]</xref>, <xref rid="pone.0057554-Gianni1" ref-type="bibr">[13]</xref>, <xref rid="pone.0057554-Yeh1" ref-type="bibr">[14]</xref>, with prior histologic studies (including one from our group) demonstrating evidence of disorganized myofibrillar morphology, myocellular vacuolization and necrosis, and interstitial fibrosis <xref rid="pone.0057554-Lightfoot1" ref-type="bibr">[9]</xref>, <xref rid="pone.0057554-Ferrans1" ref-type="bibr">[15]</xref>.</p><p>In addition to CHF, however, anthracycline exposure has been found to increase the incidence of vascular events including MI and stroke <xref rid="pone.0057554-Aleman1" ref-type="bibr">[1]</xref>, <xref rid="pone.0057554-Moser1" ref-type="bibr">[2]</xref>, <xref rid="pone.0057554-Swerdlow1" ref-type="bibr">[16]</xref>. This issue has become highly relevant as the number of cancer survivors has increased significantly over the past 20 years <xref rid="pone.0057554-Albini1" ref-type="bibr">[17]</xref>, <xref rid="pone.0057554-Du1" ref-type="bibr">[18]</xref>. For example, among 10-year survivors of breast cancer, data from 1970 through 1986 indicate that women having received adjuvant anthracycline-based chemotherapy experience an increase in MI (hazard ratio [HR]&#x0200a;=&#x0200a;2.55, 95% confidence interval [CI]&#x0200a;=&#x0200a;1.55&#x02013;4.19; <italic>p</italic>&#x0003c;0.001), and stroke (HR&#x0200a;=&#x0200a;1.85, 95% CI&#x0200a;=&#x0200a;1.25&#x02013;2.73; <italic>p</italic>&#x0200a;=&#x0200a;0.002) relative to women without cancer or the prior receipt of an anthracycline <xref rid="pone.0057554-Silber1" ref-type="bibr">[11]</xref>. As recently recognized by the National Cancer Institute, important trends are emerging regarding cancer treatment: as advanced therapeutics are reducing cancer-related illness, some of this benefit is offset by an adverse rise in morbidity and mortality from CV disease <xref rid="pone.0057554-Jensen1" ref-type="bibr">[3]</xref>. This paper presents new data that describes the effect of DOX exposure on the thickening of the walls of the coronary arterioles in hopes of determining whether acute exposure to DOX influences the coronary arteriolar microcirculation.</p><p>As demonstrated in <xref ref-type="table" rid="pone-0057554-t001">Table 1</xref>, animals in this study developed an unhealthy appearance, a decrease in weight, and a drop in LVEF upon receipt of DOX. These findings are similar to those observed in prior studies <xref rid="pone.0057554-Heon1" ref-type="bibr">[19]</xref>. As shown in <xref ref-type="table" rid="pone-0057554-t002">Table 2</xref>, total microcirculatory arteriolar wall thickness increased after the 2.5 mg/kg/week dose of DOX. This increase in arterial wall thickness was accounted for primarily by an increase in the medial component of the wall (<xref ref-type="fig" rid="pone-0057554-g002">Figure 2</xref> and <xref ref-type="table" rid="pone-0057554-t002">Table 2</xref>), and remained present after indexing the size of the arteriolar segments for the diameter of the vessel lumen (<xref ref-type="table" rid="pone-0057554-t003">Table 3</xref>). The results after indexing indicate that the increases in wall thickness were not confined to smaller or larger arterioles and not related to potential differences in vessel sizes between our treatment groups (saline, low and high dose DOX).</p><p>Since the animals in the study exhibited differences in age, weight, and total cumulative DOX dose, we also performed analyses to account for these differences. As shown in <xref ref-type="fig" rid="pone-0057554-g003">Figure 3</xref>, increases in wall thickness after high DOX exposure persisted after accounting for the age and weight of the animals as well as the cumulative dose of DOX received. Although not statistically significant, strong trends were respectively observed (<italic>p</italic>&#x0003c;0.06 to 0.09) in increases in adventitial and total wall thickness in animals receiving lower doses of DOX after accounting for age, weight and cumulative DOX dose.</p><p>There are several mechanisms which may explain the coronary arteriolar wall thickening observed in this study after DOX. Adventitial hypertrophy has been linked with oxidative inflammation, most notably NADPH oxidase <xref rid="pone.0057554-Csanyi1" ref-type="bibr">[20]</xref>. Anthracyclines are known to increase free radical production via effects on NADPH oxidase <xref rid="pone.0057554-Zhao1" ref-type="bibr">[21]</xref>. Adventitial inflammation with increased NADPH oxidase activity causes significant adventitial fibrosis and smooth muscle hypertrophy <xref rid="pone.0057554-Csanyi1" ref-type="bibr">[20]</xref>. Inflammation in the adventitial layer can exhibit strong paracrine effects on both the media and intima, and as a result, stimulate smooth muscle hypertrophy within the walls of the arterial segments <xref rid="pone.0057554-Csanyi1" ref-type="bibr">[20]</xref>, <xref rid="pone.0057554-Barker1" ref-type="bibr">[22]</xref>.</p><p>In addition to a primary effect of DOX on the media of the arterioles, other comorbidities may be exacerbated by DOX that indirectly promote increased arteriolar wall thickening. For example, increased medial thickness may result chronically from pressure overload such as elevated blood pressure which may result from increased arterial stiffness <xref rid="pone.0057554-DallaPozza1" ref-type="bibr">[23]</xref>. In this study, we did not measure blood pressure, nor did we routinely assess renal function; thus we do not have data that can address this issue.</p><p>The results of this study do not provide mechanisms to account for the increased risk of subsequent MI after anthracycline exposure. Other study results, however, have demonstrated associations between anthracycline exposure and vascular dysfunction in non-coronary vascular beds <xref rid="pone.0057554-Kuhnl1" ref-type="bibr">[24]</xref>&#x02013;<xref rid="pone.0057554-Murata1" ref-type="bibr">[28]</xref>. Bar-Joseph, et al, demonstrated vascular dysfunction acutley after exposure to DOX, and Murata, et al, demonstrated effects of DOX on cultured endothelial cells <xref rid="pone.0057554-BarJoseph1" ref-type="bibr">[27]</xref>&#x02013;<xref rid="pone.0057554-Murata1" ref-type="bibr">[28]</xref>. Inflammation from injury to the tunica media precipitates intimal hyperplasia <xref rid="pone.0057554-Chan1" ref-type="bibr">[29]</xref>, which in other studies has preceded acute coronary artery syndromes <xref rid="pone.0057554-Mehra1" ref-type="bibr">[30]</xref>. In addition, medial layers with increased thickness are not able to respond to nitric oxide to augment blood flow <xref rid="pone.0057554-Ueno1" ref-type="bibr">[31]</xref>. As such, increased medial and adventitial thickening may contribute to abnormal myocardial perfusion. Our results indicate that increased coronary artery wall thickening occurs early after exposure to the DOX, and suggests further studies are warranted to investigate the mechanism of this association and whether this increase in wall thickening is associated with reduced vasodilator reserve, premature atherosclerosis, or increased myocardial ischemia in the setting of CV stress.</p><p>There are several limitations to this study. First, this may be a phenomenon isolated to rats. As such, subsequent studies will need to be employed in other animal models and human participants to document the occurrence. Second, we are uncertain if this response would occur using other anthracycline preparations. Further studies will need to be performed to see if these changes persist with encapsulated DOX, which is used for human treatment. Third, this study focused on the anatomy of the involved coronary arterioles. Future studies need to also describe the physiologic function of coronary arteries as well as the smaller micro vessels exposed to anthracyclines.</p><p>In conclusion, early after exposure to anthracycline-based chemotherapy with DOX, microcirculatory coronary arteriolar wall segments develop increased thickening of the medial and adventitial layers leading to an overall increase in microcirculatory arteriolar wall thickness. Further studies are indicated to determine the etiology of this occurrence and whether this finding is permanent and promotes myocardial ischemia in the setting of vasodilator or exercise induced stress.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0057554-Aleman1"><label>1</label><mixed-citation publication-type="journal">
<name><surname>Aleman</surname><given-names>BM</given-names></name>, <name><surname>van den Belt-Dusebout</surname><given-names>AW</given-names></name>, <name><surname>Klokman</surname><given-names>WJ</given-names></name>, <name><surname>Van't Veer</surname><given-names>MB</given-names></name>, <name><surname>Bartelink</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Long-term cause-specific mortality of patients treated for Hodgkin's disease</article-title>. <source>J Clin Oncol</source>
<volume>21</volume>: <fpage>3431</fpage>&#x02013;<lpage>3439</lpage>.<pub-id pub-id-type="pmid">12885835</pub-id></mixed-citation></ref><ref id="pone.0057554-Moser1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Moser</surname><given-names>EC</given-names></name>, <name><surname>Noordijk</surname><given-names>EM</given-names></name>, <name><surname>van Leeuwen</surname><given-names>FE</given-names></name>, <name><surname>le Cessie</surname><given-names>S</given-names></name>, <name><surname>Baars</surname><given-names>JW</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin's Lymphoma</article-title>. <source>Blood</source>
<volume>107</volume>: <fpage>2912</fpage>&#x02013;<lpage>2919</lpage>.<pub-id pub-id-type="pmid">16339404</pub-id></mixed-citation></ref><ref id="pone.0057554-Jensen1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Jensen</surname><given-names>BV</given-names></name> (<year>2006</year>) <article-title>Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer</article-title>. <source>Semin Oncol</source>
<volume>33</volume>: <fpage>S15</fpage>&#x02013;<lpage>S21</lpage>.</mixed-citation></ref><ref id="pone.0057554-Aries1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Aries</surname><given-names>A</given-names></name>, <name><surname>Paradis</surname><given-names>P</given-names></name>, <name><surname>Lefebvre</surname><given-names>C</given-names></name>, <name><surname>Schwartz</surname><given-names>RJ</given-names></name>, <name><surname>Nemer</surname><given-names>M</given-names></name> (<year>2004</year>) <article-title>Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity</article-title>. <source>Proc Natl Acad Sci U S A</source>
<volume>101</volume>: <fpage>6975</fpage>&#x02013;<lpage>6980</lpage>.<pub-id pub-id-type="pmid">15100413</pub-id></mixed-citation></ref><ref id="pone.0057554-Kotamraju1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Kotamraju</surname><given-names>S</given-names></name>, <name><surname>Kalivendi</surname><given-names>SV</given-names></name>, <name><surname>Konorev</surname><given-names>E</given-names></name>, <name><surname>Chitambar</surname><given-names>CR</given-names></name>, <name><surname>Joseph</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Oxidant-induced iron signaling in Doxorubicin-mediated apoptosis</article-title>. <source>Methods Enzymol</source>
<volume>378</volume>: <fpage>362</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">15038980</pub-id></mixed-citation></ref><ref id="pone.0057554-LEcuyer1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>L'Ecuyer</surname><given-names>T</given-names></name>, <name><surname>Sanjeev</surname><given-names>S</given-names></name>, <name><surname>Thomas</surname><given-names>R</given-names></name>, <name><surname>Novak</surname><given-names>R</given-names></name>, <name><surname>Das</surname><given-names>L</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>DNA damage is an early event in doxorubicin-induced cardiac myocyte death</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>291</volume>: <fpage>H1273</fpage>&#x02013;<lpage>H1280</lpage>.<pub-id pub-id-type="pmid">16565313</pub-id></mixed-citation></ref><ref id="pone.0057554-Lim1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Lim</surname><given-names>CC</given-names></name>, <name><surname>Zuppinger</surname><given-names>C</given-names></name>, <name><surname>Guo</surname><given-names>X</given-names></name>, <name><surname>Kuster</surname><given-names>GM</given-names></name>, <name><surname>Helmes</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes</article-title>. <source>J Biol Chem</source>
<volume>279</volume>: <fpage>8290</fpage>&#x02013;<lpage>8299</lpage>.<pub-id pub-id-type="pmid">14676206</pub-id></mixed-citation></ref><ref id="pone.0057554-Timolati1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Timolati</surname><given-names>F</given-names></name>, <name><surname>Ott</surname><given-names>D</given-names></name>, <name><surname>Pentassuglia</surname><given-names>L</given-names></name>, <name><surname>Giraud</surname><given-names>MN</given-names></name>, <name><surname>Perriard</surname><given-names>JC</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes</article-title>. <source>J Mol Cell Cardiol</source>
<volume>41</volume>: <fpage>845</fpage>&#x02013;<lpage>854</lpage>.<pub-id pub-id-type="pmid">17005195</pub-id></mixed-citation></ref><ref id="pone.0057554-Lightfoot1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Lightfoot</surname><given-names>JC</given-names></name>, <name><surname>D'Agostino</surname><given-names>RB</given-names><suffix>Jr</suffix></name>, <name><surname>Hamilton</surname><given-names>CA</given-names></name>, <name><surname>Jordan</surname><given-names>J</given-names></name>, <name><surname>Torti</surname><given-names>FM</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Novel approach to early detection of doxorubicin cardiotoxicity by gadolinium-enhanced cardiovascular magnetic resonance imaging in an experimental model</article-title>. <source>Circ Cardiovasc Imaging</source>
<volume>3</volume>: <fpage>550</fpage>&#x02013;<lpage>558</lpage>.<pub-id pub-id-type="pmid">20622140</pub-id></mixed-citation></ref><ref id="pone.0057554-Floyd1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Floyd</surname><given-names>JD</given-names></name>, <name><surname>Nguyen</surname><given-names>DT</given-names></name>, <name><surname>Lobins</surname><given-names>RL</given-names></name>, <name><surname>Bashir</surname><given-names>Q</given-names></name>, <name><surname>Doll</surname><given-names>DC</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Cardiotoxicity of cancer therapy</article-title>. <source>J Clin Oncol</source>
<volume>23</volume>: <fpage>7685</fpage>&#x02013;<lpage>7696</lpage>.<pub-id pub-id-type="pmid">16234530</pub-id></mixed-citation></ref><ref id="pone.0057554-Silber1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Silber</surname><given-names>JH</given-names></name>, <name><surname>Cnaan</surname><given-names>A</given-names></name>, <name><surname>Clark</surname><given-names>BJ</given-names></name>, <name><surname>Paridon</surname><given-names>SM</given-names></name>, <name><surname>Chin</surname><given-names>AJ</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines</article-title>. <source>J Clin Oncol</source>
<volume>22</volume>: <fpage>820</fpage>&#x02013;<lpage>828</lpage>.<pub-id pub-id-type="pmid">14990637</pub-id></mixed-citation></ref><ref id="pone.0057554-Singal1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Singal</surname><given-names>PK</given-names></name>, <name><surname>Iliskovic</surname><given-names>N</given-names></name> (<year>1998</year>) <article-title>Doxorubicin-induced cardiomyopathy</article-title>. <source>N Engl J Med</source>
<volume>339</volume>: <fpage>900</fpage>&#x02013;<lpage>905</lpage>.<pub-id pub-id-type="pmid">9744975</pub-id></mixed-citation></ref><ref id="pone.0057554-Gianni1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Gianni</surname><given-names>L</given-names></name>, <name><surname>Herman</surname><given-names>EH</given-names></name>, <name><surname>Lipshultz</surname><given-names>SE</given-names></name>, <name><surname>Minotti</surname><given-names>G</given-names></name>, <name><surname>Sarvazyan</surname><given-names>N</given-names></name>, <etal>et al</etal> (<year>2008</year>) <article-title>Anthracycline cardiotoxicity: from bench to bedside</article-title>. <source>J Clin Oncol</source>
<volume>26</volume>: <fpage>3777</fpage>&#x02013;<lpage>3784</lpage>.<pub-id pub-id-type="pmid">18669466</pub-id></mixed-citation></ref><ref id="pone.0057554-Yeh1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>Yeh</surname><given-names>ET</given-names></name>, <name><surname>Tong</surname><given-names>AT</given-names></name>, <name><surname>Lenihan</surname><given-names>DJ</given-names></name>, <name><surname>Yusuf</surname><given-names>SW</given-names></name>, <name><surname>Swafford</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2004</year>) <article-title>Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and treatment</article-title>. <source>Circulation</source>
<volume>109</volume>: <fpage>3122</fpage>&#x02013;<lpage>3131</lpage>.<pub-id pub-id-type="pmid">15226229</pub-id></mixed-citation></ref><ref id="pone.0057554-Ferrans1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Ferrans</surname><given-names>VJ</given-names></name> (<year>1978</year>) <article-title>Overview of cardiac pathology in relation to anthracycline cardiotoxicity</article-title>. <source>Cancer Treat Rep</source>
<volume>62</volume>: <fpage>955</fpage>&#x02013;<lpage>961</lpage>.<pub-id pub-id-type="pmid">352510</pub-id></mixed-citation></ref><ref id="pone.0057554-Swerdlow1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Swerdlow</surname><given-names>AJ</given-names></name>, <name><surname>Higgins</surname><given-names>CD</given-names></name>, <name><surname>Smith</surname><given-names>P</given-names></name>, <name><surname>Cunningham</surname><given-names>D</given-names></name>, <name><surname>Hancock</surname><given-names>BW</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Myocardial infarction mortality risk after treatment for Hodgkin disease</article-title>. <source>J Natl Cancer Inst</source>
<volume>99</volume>: <fpage>206</fpage>&#x02013;<lpage>214</lpage>.<pub-id pub-id-type="pmid">17284715</pub-id></mixed-citation></ref><ref id="pone.0057554-Albini1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Albini</surname><given-names>A</given-names></name>, <name><surname>Pennesi</surname><given-names>G</given-names></name>, <name><surname>Donatelli</surname><given-names>F</given-names></name>, <name><surname>Cammarota</surname><given-names>R</given-names></name>, <name><surname>De Flora</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Cardiotoxicity of anticancer drugs: the need for cardio-oncology</article-title>. <source>J Natl Cancer Inst</source>
<volume>102</volume>: <fpage>14</fpage>&#x02013;<lpage>25</lpage>.<pub-id pub-id-type="pmid">20007921</pub-id></mixed-citation></ref><ref id="pone.0057554-Du1"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Du</surname><given-names>XL</given-names></name>, <name><surname>Fox</surname><given-names>EE</given-names></name>, <name><surname>Lai</surname><given-names>D</given-names></name> (<year>2008</year>) <article-title>Competing causes of death for women with breast cancer and change over time</article-title>. <source>Am J Clin Oncol</source>
<volume>31</volume>: <fpage>105</fpage>&#x02013;<lpage>116</lpage>.<pub-id pub-id-type="pmid">18391593</pub-id></mixed-citation></ref><ref id="pone.0057554-Heon1"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Heon</surname><given-names>S</given-names></name>, <name><surname>Bernier</surname><given-names>M</given-names></name>, <name><surname>Servant</surname><given-names>N</given-names></name>, <name><surname>Dostanic</surname><given-names>S</given-names></name>, <name><surname>Wang</surname><given-names>C</given-names></name>, <etal>et al</etal> (<year>2003</year>) <article-title>Dexrazoxane does not protect against doxorubicin-induced damage in young rats</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>285</volume>: <fpage>H499</fpage>&#x02013;<lpage>H506</lpage>.<pub-id pub-id-type="pmid">12714334</pub-id></mixed-citation></ref><ref id="pone.0057554-Csanyi1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Csanyi</surname><given-names>G</given-names></name>, <name><surname>Taylor</surname><given-names>WR</given-names></name>, <name><surname>Pagano</surname><given-names>PJ</given-names></name> (<year>2009</year>) <article-title>NOX and inflammation in the vascular adventitia</article-title>. <source>Free Radic Biol Med</source>
<volume>47</volume>: <fpage>1254</fpage>&#x02013;<lpage>1266</lpage>.<pub-id pub-id-type="pmid">19628034</pub-id></mixed-citation></ref><ref id="pone.0057554-Zhao1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Zhao</surname><given-names>Y</given-names></name>, <name><surname>McLaughlin</surname><given-names>D</given-names></name>, <name><surname>Robinson</surname><given-names>E</given-names></name>, <name><surname>Harvey</surname><given-names>AP</given-names></name>, <name><surname>Hookham</surname><given-names>MB</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with Doxorubicin chemotherapy</article-title>. <source>Cancer Res</source>
<volume>70</volume>: <fpage>9287</fpage>&#x02013;<lpage>9297</lpage>.<pub-id pub-id-type="pmid">20884632</pub-id></mixed-citation></ref><ref id="pone.0057554-Barker1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Barker</surname><given-names>SG</given-names></name>, <name><surname>Talbert</surname><given-names>A</given-names></name>, <name><surname>Cottam</surname><given-names>S</given-names></name>, <name><surname>Baskerville</surname><given-names>PA</given-names></name>, <name><surname>Martin</surname><given-names>JF</given-names></name> (<year>1993</year>) <article-title>Arterial intimal hyperplasia after occlusion of the adventitial vasa vasorum in the pig</article-title>. <source>Arterioscler</source>
<volume>Thromb13</volume>: <fpage>70</fpage>&#x02013;<lpage>77</lpage>.</mixed-citation></ref><ref id="pone.0057554-DallaPozza1"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Dalla Pozza</surname><given-names>R</given-names></name>, <name><surname>Beyerlein</surname><given-names>A</given-names></name>, <name><surname>Thilmany</surname><given-names>C</given-names></name>, <name><surname>Weissenbacher</surname><given-names>C</given-names></name>, <name><surname>Netz</surname><given-names>H</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>The effect of cardiovascular risk factors on the longitudinal evolution of the carotid intima medial thickness in children with type 1 diabetes mellitus</article-title>. <source>Cardiovasc Diabetol</source>
<volume>10</volume>: <fpage>53</fpage>.<pub-id pub-id-type="pmid">21679428</pub-id></mixed-citation></ref><ref id="pone.0057554-Kuhnl1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>Kuhnl</surname><given-names>A</given-names></name>, <name><surname>Pelisek</surname><given-names>J</given-names></name>, <name><surname>Tian</surname><given-names>W</given-names></name>, <name><surname>Kuhlmann</surname><given-names>M</given-names></name>, <name><surname>Rolland</surname><given-names>PH</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>C-type natriuretic peptide inhibits constrictive remodeling without compromising re-endothelialization in balloon-dilated renal arteries</article-title>. <source>J Endovasc Ther</source>
<volume>12</volume>: <fpage>171</fpage>&#x02013;<lpage>182</lpage>.<pub-id pub-id-type="pmid">15823063</pub-id></mixed-citation></ref><ref id="pone.0057554-Wolf1"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Wolf</surname><given-names>MB</given-names></name>, <name><surname>Baynes</surname><given-names>JW</given-names></name> (<year>2006</year>) <article-title>The anti-cancer drug, doxorubicin, causes oxidant stress-induced endothelial dysfunction</article-title>. <source>Biochim Biophys Acta</source>
<volume>1760</volume>: <fpage>267</fpage>&#x02013;<lpage>271</lpage>.<pub-id pub-id-type="pmid">16337743</pub-id></mixed-citation></ref><ref id="pone.0057554-Chaosuwannakit1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Chaosuwannakit</surname><given-names>N</given-names></name>, <name><surname>D'Agostino</surname><given-names>R</given-names><suffix>Jr</suffix></name>, <name><surname>Hamilton</surname><given-names>CA</given-names></name>, <name><surname>Lane</surname><given-names>KS</given-names></name>, <name><surname>Ntim</surname><given-names>WO</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Aortic stiffness increases upon receipt of anthracycline chemotherapy</article-title>. <source>J Clin Oncol</source>
<volume>28</volume>: <fpage>166</fpage>&#x02013;<lpage>172</lpage>.<pub-id pub-id-type="pmid">19901105</pub-id></mixed-citation></ref><ref id="pone.0057554-BarJoseph1"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Bar-Joseph</surname><given-names>H</given-names></name>, <name><surname>Ben-Aharon</surname><given-names>I</given-names></name>, <name><surname>Tzabari</surname><given-names>M</given-names></name>, <name><surname>Tsarfaty</surname><given-names>G</given-names></name>, <name><surname>Stemmer</surname><given-names>SM</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels</article-title>. <source>PLoS One</source>
<volume>6</volume>
<issue>(9)</issue>
<fpage>e23492</fpage> Epub 2011 Sep 9.<pub-id pub-id-type="pmid">21931602</pub-id></mixed-citation></ref><ref id="pone.0057554-Murata1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Murata</surname><given-names>T</given-names></name>, <name><surname>Yamawaki</surname><given-names>H</given-names></name>, <name><surname>Yoshimoto</surname><given-names>R</given-names></name>, <name><surname>Hori</surname><given-names>M</given-names></name>, <name><surname>Sato</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2001</year>) <month>10</month>
<day>19</day>
<article-title>Chronic effect of doxorubicin on vascular endothelium assessed by organ culture study</article-title>. <source>Life Sci</source>. <volume>69</volume>
<issue>(22)</issue>
<fpage>2685</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">11712671</pub-id></mixed-citation></ref><ref id="pone.0057554-Chan1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Chan</surname><given-names>J</given-names></name>, <name><surname>Prado-Lourenco</surname><given-names>L</given-names></name>, <name><surname>Khachigian</surname><given-names>LM</given-names></name>, <name><surname>Bennett</surname><given-names>MR</given-names></name>, <name><surname>Di Bartolo</surname><given-names>BA</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappa B-dependent manner</article-title>. <source>Circ Res</source>
<volume>106</volume>: <fpage>1061</fpage>&#x02013;<lpage>1071</lpage>.<pub-id pub-id-type="pmid">20150555</pub-id></mixed-citation></ref><ref id="pone.0057554-Mehra1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Mehra</surname><given-names>MR</given-names></name>, <name><surname>Ventura</surname><given-names>HO</given-names></name>, <name><surname>Stapleton</surname><given-names>DD</given-names></name>, <name><surname>Smart</surname><given-names>FW</given-names></name>, <name><surname>Collins</surname><given-names>TC</given-names></name>, <etal>et al</etal> (<year>1995</year>) <article-title>Presence of severe intimal thickening by intravascular ultrasonography predicts cardiac events in cardiac allograft vasculopathy</article-title>. <source>J Heart Lung Transplant</source>
<volume>14</volume>: <fpage>632</fpage>&#x02013;<lpage>639</lpage>.<pub-id pub-id-type="pmid">7578168</pub-id></mixed-citation></ref><ref id="pone.0057554-Ueno1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Ueno</surname><given-names>H</given-names></name>, <name><surname>Kanellakis</surname><given-names>P</given-names></name>, <name><surname>Agrotis</surname><given-names>A</given-names></name>, <name><surname>Bobik</surname><given-names>A</given-names></name> (<year>2000</year>) <article-title>Blood flow regulates the development of vascular hypertrophy, smooth muscle cell proliferation, and endothelial cell nitric oxide synthase in hypertension</article-title>. <source>Hypertension</source>
<volume>36</volume>: <fpage>89</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">10904018</pub-id></mixed-citation></ref></ref-list></back></article>